pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·6h ago·1 min read
save

Anthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’

Nov 19, 2026·read at Fierce Biotech ↗

On the same day Anthropic staged a record-shattering IPO on Nasdaq, the artificial intelligence tech giant’s lone pharmaceutical board member, Novartis CEO Vas Narasimhan, was in London pitching investors on how the Swiss drugmaker is using AI to shrink drug development timelines and one day solve “biological latency.”

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 12h agoVaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncologyFierce Biotech
  • 13h agonChroma halves headcount, calls time on trial of potential HBV ‘cure’Fierce Biotech
  • 14h agoIsomorphic adds Merck to AI drug discovery roster days after $5B raiseFierce Biotech
  • 16h agoTeva loses R&D head Eric Hughes amid push to grow innovative medicines businessFierce Biotech
  • 18h agoNovartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentFierce Biotech